Synthetic Ease and Exceptional In Vivo Performance of Pyrazole-based Cyclometallated Iridium Complexes

Vanesa Fernández-Moreira,M. Concepción Gimeno,Marta Redrado,Eduardo Romanos,Andrea Benedí Visiedo,Guillermo Canudo-Barreras,Isabel Marzo

DOI: https://doi.org/10.1039/d3qi02355a

IF: 7.779

2024-02-06

Inorganic Chemistry Frontiers

Abstract:Two luminescent cyclometallated Ir III complexes of the type [Ir(C^N) 2 (N^N)] x (X = 0 ( 1 ), and X = +1 ( 2 )) were prepared using methyl 2-phenylquinoline-4-carboxylate as C^N ligands and either a deprotonated or protonated 3-(2-pyridyl)pyrazole as the N^N chelate. The synthesis followed a well-established and straightforward procedure. Photophysical analysis unveiled their remarkable properties, featuring phosphorescent red and orange emissions attributed to 3 MLCT and 3 LLCT transitions, with high emissive quantum yields in degassed DMSO solutions. Importantly, these complexes exhibited dual functionality as potent chemotherapeutic agents and photosensitisers, with their effectiveness tailored to specific cancer cell lines. Phototherapeutic treatment was particularly effective against lung cancer A549 cells, while a chemotherapeutic approach yielded superior results against breast cancer 4T1-luc2 cells. Both complexes primarily targeted lysosomes, leading to cell death through apoptotic pathways, with IC50 values in the nanomolar range. Importantly, they demonstrated no cytotoxicity against lymphocytes, mimicking the behaviour observed in healthy cells. Encouragingly, 1 and 2 exhibited minimal in vivo toxicity. The most striking finding was the exceptional chemotherapeutic efficacy of complexes 1 and 2 against 4T1-luc2 cells in BALB/c mice. These complexes surpassed the performance of the clinically employed 5-fluorouracil, especially at early tumor stages, significantly retarding 4T1-luc2 proliferation. Further investigations at vascularised and organised tumor stages revealed that complex 1 could reduce tumor size by half compared to untreated mice, which was also confirmed through tumoral weight analysis. While these findings are preliminary, the outstanding performance of these complexes at early tumor stages against breast cancer 4T1-luc2 in vivo, their selective therapeutic feasibility (chemotherapy vs. PDT) tailored to specific cancerous cell lines, and their straightforward synthetic design make them highly attractive candidates for cancer treatment.

chemistry, inorganic & nuclear

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to develop iridium - based complexes with dual functions. These complexes can be used as both chemotherapeutic drugs and photosensitizers, especially for specific types of cancer cells (such as lung cancer A549 cells and breast cancer 4T1 - luc2 cells). Specifically, the goals of the paper include:

1. **Design and synthesize iridium - based complexes with simple methods and the ability to target lysosomes**:
- Achieve specific targeting of lysosomes by introducing pyrazole groups in the design of bidentate ligands (N^N).
- Select appropriate monodentate ligands (C^N) to expand the optical properties, making them suitable for the near - infrared region, thereby improving the efficiency of photodynamic therapy.

2. **Evaluate the photophysical properties of these complexes**:
- Study the absorption and emission spectra of these complexes in DMSO solutions, as well as their quantum yields and lifetimes.
- Explore the stabilities of these complexes under different conditions, especially the photostability under physiological conditions.

3. **Evaluate the cytotoxicity and photocytotoxicity of these complexes**:
- Use the MTT reduction assay to evaluate the cytotoxicity and photocytotoxicity of these complexes in different cell lines (A549 and 4T1 - luc2).
- Analyze the apoptosis and necrosis of cells by flow cytometry to further verify the cell death mechanisms of these complexes.
- Evaluate the cytotoxicity of these complexes in healthy cells (such as lymphocytes) to determine their selectivity.

4. **Explore the in vivo therapeutic effects of these complexes**:
- Evaluate the chemotherapeutic effects of these complexes on 4T1 - luc2 cells in BALB/c mice through in vivo experiments, especially compared with the clinically commonly used 5 - fluorouracil.
- Study the therapeutic effects of these complexes at different tumor stages (such as vascularized and organized tumors).

Through the above research, the paper aims to develop a new type of anti - cancer drug with high selectivity, low toxicity and high - efficiency therapeutic effects, and provide a theoretical basis for its clinical application.